Ambrosia Biosciences

Ambrosia Biosciences Announces Late-Breaking Poster Presentations at ObesityWeek® 2026

Poster presentations will feature the nonclinical profiles of Ambrosia's novel oral small molecule GLP-1 receptor agonist intended for once-weekly dosing and novel oral small molecule GIP receptor antagonist

BOULDER, Colo., November 10, 2026 -- Ambrosia Biosciences Inc. ("Ambrosia") today announced it will present two late-breaking posters at ObesityWeek® 2026, the Obesity Society's 44th Annual Meeting, November 14-17 in Washington, D.C. The poster presentations will feature the nonclinical profiles of Ambrosia's novel oral small molecule GLP-1 receptor agonist intended for once-weekly dosing and novel oral small molecule GIP receptor antagonist.

Presentation details

Title: Discovery and Nonclinical Profile of AMB-895, a Long-Acting and Novel Oral Small Molecule GLP-1R Agonist
Poster #: 463
Room: Gaylord National Resort & Convention Center, Exhibit Hall BCD
Date: Sunday, November 15, 2026
Time: 2:30 – 3:30 PM ET

Title: Discovery and Nonclinical Profile of AMB-131, a Novel, Oral Small Molecule GIP Receptor Antagonist
Poster #: 470
Room: Gaylord National Resort & Convention Center, Exhibit Hall BCD
Date: Sunday, November 15, 2026
Time: 2:30 – 3:30 PM ET

About Ambrosia Biosciences Inc.

Ambrosia Biosciences Inc. is a privately held drug discovery company developing next-generation oral small molecule therapies for obesity and other metabolic disorders. By integrating structurally-enabled drug design with in-house medicinal chemistry and biology capabilities, Ambrosia is advancing a complementary pipeline of differentiated therapies. Ambrosia aims to expand access to cardiometabolic therapies that improve the patient experience while reducing the cost and complexity of treatment. For more information, please visit www.ambrosiabiosciences.com.

Forward-Looking Statement

This press release may contain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements. Words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements.

These forward-looking statements include, among others, statements regarding Ambrosia's goals, strategic plans and the advancement and expansion of its development pipeline. Such statements are based on management's current expectations and involve risks, uncertainties and assumptions, including the inherent risks and uncertainties of drug discovery and development. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Moreover, Ambrosia operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Ambrosia undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Investor & Media Contact:

Ambrosia Biosciences
Andrea Flynn, Ph.D.
Chief Business Officer
PR@ambrosia.health